How to Get Vyvanse in Kentucky: Prescriptions, Telehealth, and Pharmacies

What Vyvanse Is and Why It Requires a Special Prescription Process

Vyvanse is an FDA-approved central nervous system stimulant indicated for ADHD in patients aged 6 and older and for moderate-to-severe binge eating disorder (BED) in adults. The active molecule, lisdexamfetamine, is a prodrug that converts to d-amphetamine after oral ingestion, which is one reason its abuse-deterrence profile differs from immediate-release amphetamine salts.

The FDA first approved lisdexamfetamine for ADHD in 2007 and expanded approval to BED in 2015 [1]. Because it contains amphetamine, the DEA classifies it as a Schedule II substance. That classification carries strict prescribing rules regardless of which state you live in.

Why Schedule II Status Matters in Kentucky

Schedule II controlled substances cannot be called in verbally to a pharmacy in most circumstances. Kentucky follows federal DEA rules requiring a written or electronic prescription for each fill. Refills on a Schedule II prescription are not permitted. Your prescriber must issue a new prescription for every 30-day supply.

Kentucky also participates in the Prescription Drug Monitoring Program (PDMP), called the Kentucky All Schedule Prescription Electronic Reporting system (KASPER). Every prescriber must query KASPER before issuing a Schedule II medication. Patients should expect this to happen at every visit [2].

Approved Indications and Clinical Evidence

The Phase III ADHD trial data supporting lisdexamfetamine used the Conners' ADHD Rating Scale and showed statistically significant reductions in symptom scores compared with placebo across pediatric and adult populations [3]. For BED, a randomized controlled trial (N=390) published in the International Journal of Eating Disorders demonstrated that lisdexamfetamine 50 mg and 70 mg produced significantly greater reductions in binge eating days per week versus placebo (P<0.001) [4].

Wigal et al. (J Atten Disord, 2017) examined long-term lisdexamfetamine safety over a 12-month open-label extension, finding that mean ADHD-RS-IV total scores improved from baseline through week 52 with a tolerability profile consistent with the original key studies [5]. That long-term dataset is frequently cited by Kentucky clinicians when justifying continued prescribing to insurance reviewers.

Who Can Prescribe Vyvanse in Kentucky

Physicians (MD and DO)

Any Kentucky-licensed MD or DO with a valid DEA registration may prescribe Schedule II stimulants. Most psychiatrists, many primary care physicians, and some pediatricians regularly prescribe lisdexamfetamine. A psychiatrist is not required by law, though insurers sometimes prefer a psychiatric evaluation for the first authorization of a Schedule II stimulant.

Nurse Practitioners and Physician Assistants

Kentucky law grants full practice authority to Advanced Practice Registered Nurses (APRNs) who have completed the transition-to-practice requirement (two years or 4,000 hours under a collaborative agreement). APRNs with full practice authority may prescribe Schedule II controlled substances independently [6]. Physician Assistants (PAs) in Kentucky prescribe under a supervision agreement with a physician, and that agreement must explicitly authorize Schedule II prescribing. Patients should confirm their telehealth provider's license type before booking an appointment.

Telehealth Prescribers

After the COVID-19 Public Health Emergency, the DEA proposed new rules for telemedicine prescribing of controlled substances. As of mid-2025, the DEA's telemedicine framework allows qualified providers to prescribe Schedule II stimulants via telehealth for ADHD if the patient has had at least one in-person medical evaluation by any DEA-registered practitioner [7]. Some telehealth platforms serving Kentucky, including services that connect patients with board-certified psychiatrists, are structured to satisfy this requirement.

How to Get a Vyvanse Prescription in Kentucky: Step by Step

Step 1: Choose Your Care Setting

Patients can pursue an evaluation through three main routes in Kentucky.

• In-person psychiatry or primary care. Referral wait times for psychiatrists in rural Kentucky counties can exceed 90 days [8]. Primary care physicians often have shorter wait times and can prescribe for straightforward adult ADHD presentations.
• Telehealth psychiatry or ADHD specialist. Several telehealth platforms operate in Kentucky and can see patients within days. See the telehealth section below.
• Federally Qualified Health Centers (FQHCs). Kentucky has 24 FQHC grantees operating more than 300 service delivery sites, many offering behavioral health and prescribing services on a sliding-fee scale [9].

Step 2: Prepare Your Documentation

Bring or upload the following before your evaluation.

• Prior ADHD diagnoses, psychological testing, or IEP/504 documentation
• List of all current medications (KASPER will also be checked)
• Insurance card and photo ID
• Prior records of stimulant treatment, if any, including doses and responses
• For BED: a log of binge episodes and any prior behavioral therapy records

Step 3: The Clinical Evaluation

A complete ADHD evaluation for adults typically includes a structured clinical interview, completion of a validated rating scale such as the Adult ADHD Self-Report Scale (ASRS) or Conners' Adult ADHD Rating Scales (CAARS), and a review of symptom history dating to childhood [10]. Cardiovascular screening is standard. Blood pressure, heart rate, and a brief cardiac history are documented before any stimulant is started.

No blood tests are mandated by the FDA label before initiating lisdexamfetamine. Many Kentucky clinicians order a basic metabolic panel and thyroid function tests to rule out secondary causes of attention or mood symptoms.

Step 4: Prior Authorization

Most Kentucky commercial insurers require prior authorization (PA) for brand-name Vyvanse. The PA process requires your prescriber to submit clinical documentation demonstrating that the ADHD or BED diagnosis meets medical necessity criteria and, for some plans, that at least one alternative stimulant was tried and failed. Common documentation elements include:

• Validated rating scale scores
• Duration of symptoms and functional impairment evidence
• Record of any prior stimulant trials and outcomes
• Prescriber's clinical notes from the evaluation visit

PA approval typically takes 3 to 10 business days. Urgent PA requests can be submitted when a patient's functional impairment is severe.

Step 5: Filling the Prescription

Once the PA is approved, your prescriber issues a Schedule II electronic prescription (e-prescription) directly to your preferred Kentucky pharmacy. You cannot transfer a Schedule II prescription between pharmacies after partial fill unless state law explicitly permits it. Kentucky law does allow partial dispensing of Schedule II prescriptions if the pharmacist cannot fill the entire quantity; the remaining portion must be filled within 72 hours [11].

Telehealth Options for Vyvanse in Kentucky

Telehealth prescribing of Vyvanse is legal in Kentucky. The state's telehealth parity law requires that services delivered via telehealth are covered under the same terms as equivalent in-person services for most commercial insurance plans [12].

The HealthRX clinical team has reviewed the standard telehealth pathway for Schedule II stimulant prescribing in Kentucky and identified three decision points that most commonly cause delays for patients.

Decision Point 1: In-person visit requirement. Under the current DEA framework, patients who have never had an in-person evaluation with any DEA-registered practitioner may need to complete one before a telehealth provider can prescribe a Schedule II drug. Patients who have previously seen any physician and have records on file typically clear this requirement without an additional in-office visit.

Decision Point 2: KASPER query. Telehealth providers licensed in Kentucky must query KASPER before prescribing. Patients should ensure their legal name and date of birth are entered correctly in the platform to avoid query delays.

Decision Point 3: Pharmacy coordination. Some telehealth platforms send prescriptions only to specific pharmacy networks. Confirm your preferred Kentucky pharmacy is in-network with your telehealth provider before completing the visit.

Telehealth ADHD platforms that operate in Kentucky include services connecting patients with psychiatrists, psychiatric nurse practitioners, and in some cases primary care physicians with ADHD prescribing experience. Average time from first telehealth appointment to prescription sent: 1 to 3 business days for patients with prior documentation. Without prior records, the timeline extends by the time needed to gather collateral information.

Vyvanse Pharmacy Access in Kentucky

Chain Pharmacies

Major retail pharmacy chains operating in Kentucky (including CVS, Walgreens, Walmart Pharmacy, and Kroger Pharmacy) are licensed to dispense Schedule II controlled substances. Lisdexamfetamine generic capsules became available in 2023 after Takeda's patent exclusivity period ended. Generic lisdexamfetamine is considerably less expensive than brand Vyvanse and is therapeutically equivalent by FDA bioequivalence standards [1].

Independent and 503A Compounding Pharmacies

503A pharmacies in Kentucky may compound lisdexamfetamine for individual patients when a valid prescription exists and the compounded preparation is not essentially a copy of a commercially available product. This matters for patients who need a specific dose or formulation not available commercially, or who have difficulty swallowing standard capsules. Patients should verify that any compounding pharmacy they use holds a current Kentucky Board of Pharmacy license.

Drug Shortages

The national lisdexamfetamine shortage, which began in 2022 and continued into 2024, affected Kentucky pharmacies. The FDA's drug shortage database is the most current resource for real-time supply status [13]. If your preferred pharmacy is out of stock, your prescriber may contact other pharmacies on your behalf; the prescription cannot simply be transferred to a second pharmacy for a Schedule II drug, but the prescriber can issue a new prescription to a different pharmacy if the original has not been partially filled.

Cost and Savings Programs

Brand-name Vyvanse carries a list price above $400 for a 30-day supply. Takeda's savings card program reduces out-of-pocket cost for eligible commercially insured patients. Generic lisdexamfetamine ranges from approximately $80 to $180 at Kentucky pharmacies depending on dose, quantity, and whether GoodRx or a similar discount program is applied. Kentucky Medicaid (Medicaid managed care) does not currently cover Vyvanse for ADHD or BED on its preferred drug list; Medicaid patients are typically directed to generic amphetamine mixed salts or generic methylphenidate formulations.

Prior Authorization: What Kentucky Insurers Require

Kentucky commercial insurers vary in their PA criteria, but the most common requirements across Anthem, Humana, and Aetna Kentucky plans include the following.

• Documented DSM-5 diagnosis of ADHD or BED by a licensed clinician
• At least one validated symptom scale score (ASRS, CAARS, or Conners' for pediatric patients)
• For BED: documentation that cognitive behavioral therapy (CBT) was attempted or that the patient is concurrently enrolled in a behavioral program
• Evidence of functional impairment (occupational, academic, or interpersonal)
• Step therapy: some plans require a trial of generic amphetamine mixed salts (Adderall generics) or generic methylphenidate ER before approving Vyvanse [14]

When step therapy applies, a prescriber can often submit a step-therapy exception if the patient has a documented clinical reason why alternative stimulants are contraindicated or previously failed. Documented adverse effects (e.g., rebound dysphoria with immediate-release amphetamine), failure to achieve adequate symptom control, or specific medical comorbidities often satisfy exception criteria.

The American Academy of Child and Adolescent Psychiatry's practice parameter states: "Medications should be considered the primary treatment for most school-age children, adolescents, and adults" with ADHD, a position that Kentucky prescribers cite in PA appeals [15].

Cardiovascular Considerations Before Starting Vyvanse

All stimulant medications carry an FDA black box warning noting that amphetamines have a high potential for abuse. The full prescribing information also advises caution in patients with known structural cardiac abnormalities, cardiomyopathy, serious heart rhythm disorders, coronary artery disease, or other serious cardiac conditions [1].

Before starting lisdexamfetamine in Kentucky, most prescribers follow the American Heart Association's 2008 scientific statement recommending a thorough cardiovascular history and physical examination, with an electrocardiogram considered in patients with a personal or family history of cardiac disease [16]. Blood pressure and pulse should be recorded at baseline and at each follow-up visit.

Stimulant Effects on Blood Pressure and Heart Rate

Lisdexamfetamine produces modest increases in heart rate and blood pressure in clinical trials. Mean increases of approximately 3 to 5 mmHg systolic and 2 to 4 mmHg diastolic have been reported at therapeutic doses [3]. Patients with pre-existing hypertension should have blood pressure optimized before initiating any stimulant and should be monitored at least monthly during dose titration.

Drug Interactions

Monoamine oxidase inhibitors (MAOIs) are absolutely contraindicated with lisdexamfetamine; concurrent use may cause hypertensive crisis. A 14-day washout period after the last MAOI dose is required before starting any amphetamine. Serotonergic medications, alkalinizing urinary agents (e.g., sodium bicarbonate), and acidifying agents can alter lisdexamfetamine blood levels. Kentucky prescribers should review the complete interaction list in the FDA label before co-prescribing [1].

Monitoring During Vyvanse Treatment in Kentucky

Standard monitoring for patients maintained on lisdexamfetamine includes the following intervals.

• Every 30 days (first 3 months): Blood pressure, pulse, symptom rating scale, sleep quality, and appetite assessment
• Every 3 to 6 months (maintenance): Weight, height (in pediatric patients), cardiovascular assessment, and substance use screen via KASPER query
• Annually: Structured reassessment of ADHD or BED diagnosis, review of whether the current dose remains appropriate, and discussion of treatment breaks if clinically appropriate

The FDA label notes that growth should be monitored in pediatric patients, as stimulants may suppress appetite and transiently slow height velocity [1].

Transferring a Vyvanse Prescription to Kentucky

Patients relocating to Kentucky from another state cannot simply transfer a partially used Schedule II prescription. Federal law prohibits the transfer of Schedule II prescriptions between pharmacies. Your options are:

1. Ask your out-of-state prescriber to send a new written or electronic prescription to a Kentucky pharmacy (this is legal if your prescriber holds a valid DEA number; their state license covers prescriptions sent to pharmacies in the patient's home state in most but not all circumstances, so confirm with the prescriber).
2. Establish care with a Kentucky-licensed prescriber, bring prior records, and have a new prescription issued.
3. Use a multistate telehealth provider who is licensed in both your prior state and Kentucky, which may reduce the time needed to re-establish care.

The Kentucky Board of Medical Licensure maintains a current list of licensee lookup tools at its official website; patients can verify that a new prescriber is licensed in the state before their first appointment [17].

Special Populations in Kentucky

Pediatric Patients (Ages 6 to 12)

Parents seeking Vyvanse for a child in Kentucky typically start with the child's pediatrician or a developmental-behavioral pediatrician. School documentation (IEP, 504 plan, or teacher rating scales) significantly speeds evaluation. The Conners' Teacher Rating Scale is one of several standardized instruments used to gather school-based data [10].

College Students

University health centers at the University of Kentucky, University of Louisville, and Western Kentucky University are authorized to prescribe Schedule II stimulants. Students should bring prior diagnostic documentation because on-campus prescribers may have limited visit time for de novo comprehensive evaluations.

Patients With Binge Eating Disorder

BED is often underdiagnosed in Kentucky primary care. The FDA-approved dosing for BED begins at 30 mg per day and titrates to 50 mg or 70 mg weekly as tolerated. A concurrent behavioral program improves outcomes; lisdexamfetamine is the only FDA-approved pharmacotherapy for moderate-to-severe BED [4].